PCRC-Supported Legacy Intervention in Pediatric Palliative Care

Status Completed

Clinical Trial Summary

This trial studies how well a web-based legacy intervention works in improving the quality of life in caregivers and younger patients with cancer that has come back (recurrent) or does not respond to treatment (refractory). Legacy-making, defined as doing or saying something to be remembered, may reduce the suffering of children with cancer and their caregivers. Currently, there is little information about what kinds of legacy-making activities are helpful from the perspective of children. Using a web-based digital storytelling intervention, this study may help researchers examine what children think about these legacy-making activities and what kinds of activities might be helpful to them.

Clinical Trial Description

PRIMARY OBJECTIVES: I. To examine the impact of legacy-making on coping strategies and adjustment outcomes among children with refractory or relapsed cancer. II. To examine the impact of legacy-making on coping strategies and adjustment outcomes among parent caregivers. III. To examine the process of implementing a web-based legacy-making intervention for children with refractory or relapsed cancer and their parent caregivers by obtaining parent self-reports (e.g., What did you and your child-like/not like about the intervention? How difficult was it to complete the intervention? What made it difficult? What else you would like to teach us?). OUTLINE: Patients are randomized to 1 of 2 groups. GROUP I: Patients participate in a web-based legacy intervention by answering questions about themselves and uploading videos, photographs, and music to create a digital story within 2 weeks. GROUP II: Patients receive standard of care. Patients have the option to participate in the web-based legacy intervention after 2 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04059393
Study type	Interventional
Source	Vanderbilt-Ingram Cancer Center
Contact
Status	Completed
Phase	N/A
Start date	July 27, 2015
Completion date	June 5, 2018

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03439085` - DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers	Phase 2
Active, not recruiting	`NCT01582191` - Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer	Phase 1
Active, not recruiting	`NCT02152254` - Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II)	N/A
Recruiting	`NCT01790152` - Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Active, not recruiting	`NCT03856060` - Videos and Questionnaires in Assessing Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits	N/A
Completed	`NCT04186884` - Caregiver Burden, Quality of Life, and Symptom Distress at Different Palliative Cancer Care Settings
Active, not recruiting	`NCT01552434` - Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease	Phase 1
Active, not recruiting	`NCT03021486` - Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer	Phase 2/Phase 3
Completed	`NCT01624766` - Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers	Phase 1
Active, not recruiting	`NCT04053517` - Financial Distress in Advanced Cancer Patients
Active, not recruiting	`NCT03743649` - Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care	Phase 2/Phase 3
Completed	`NCT02646319` - Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations	Early Phase 1
Completed	`NCT04089488` - Incidence and Prevalence of Cancer in People Living With HIV/AIDS at Cancer Centers in Latin America
Completed	`NCT01531361` - Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations	Phase 1
Active, not recruiting	`NCT02286687` - Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes	Phase 2
Active, not recruiting	`NCT03525873` - Methylphenidate and Physical Activity to Reduce Cancer Related Fatigue Due to Anti PD1 Immunotherapy	Phase 3
Active, not recruiting	`NCT02491632` - Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer	Phase 2/Phase 3
Active, not recruiting	`NCT02595866` - Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer	Phase 1
Completed	`NCT04409314` - Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy